[PDF][PDF] Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer …
E Van Cutsem, J Tabernero, R Lakomy, H Prenen… - J Clin …, 2012 - researchgate.net
E Van Cutsem, J Tabernero, R Lakomy, H Prenen, J Prausová, T Macarulla, P Ruff…
J Clin Oncol, 2012•researchgate.netPurpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a
fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin,
and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with
bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the
effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in
the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin …
fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin,
and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with
bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the
effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in
the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin …
Purpose
Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab.
researchgate.net